The effects of amicar and TXA on lumbar spine fusion in an animal model

Spine

Volumn 39, Issue 19, 2014, Pages

  Cuellar, Jason M ^a   Yoo, Andrew ^a   Tovar, Nick ^b   Coelho, Paulo G ^b   Jimbo, Ryo ^c   Vandeweghe, Stefan ^d   Kirsch, Thorsten ^a   Quirno, Martin ^a   Errico, Thomas J ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c MALMÖ UNIVERSITY   (Sweden)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

Amicar; antifibrinolytic; epsilon aminocaproic acid; micro CT; mouse; posterolateral spine fusion; tranexamic acid; TXA

Indexed keywords

AMINOCAPROIC ACID; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT; PLASMIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE GRAFT; BONE MASS; ILIAC CREST; LUMBAR SPINE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; SPINE FUSION; SPINE RADIOGRAPHY; WILD TYPE; ANIMAL; BLOOD LOSS, SURGICAL; BONE MINERALIZATION; C57BL MOUSE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG EFFECTS; LUMBAR VERTEBRA; METABOLISM; MOUSE; RADIOGRAPHY; RANDOMIZATION; SINGLE BLIND PROCEDURE; SURGERY;

AMINOCAPROIC ACID; ANIMALS; ANTIFIBRINOLYTIC AGENTS; BLOOD LOSS, SURGICAL; CALCIFICATION, PHYSIOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYSIN; LUMBAR VERTEBRAE; MICE; MICE, INBRED C57BL; OSTEOBLASTS; RANDOM ALLOCATION; SINGLE-BLIND METHOD; SPINAL FUSION; TOMOGRAPHY, X-RAY COMPUTED; TRANEXAMIC ACID;

EID: 84907423690     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0000000000000488     Document Type: Article

References (32)

1. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001;3:CD001886.
2. Urban MK, Beckman J, Gordon M, et al. The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery. Spine (Phila Pa 1976) 2001;26:1152-6.
3. Tzortzopoulou A, Cepeda MS, Schumann R, et al. Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database Syst Rev 2008;3:CD006883.
4. Thompson GH, Florentino-Pineda I, Poe-Kochert C. The role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis. Spine (Phila Pa 1976) 2005;30:S94-9.
5. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57:1005-32.
6. Yang ZG, Chen WP, Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Jt Surg 2012;94:1153-9.
7. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004;128:442-8.
8. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, et al. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: a meta-analysis. Circulation 1999;99:81-9.
9. Maniar RN, Kumar G, Singhi T, et al. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res 2012;470:2605-12.
10. Toriseva M, Kahari VM. Proteinases in cutaneous wound healing. Cell Mol Life Sci 2009;66:203-24.
11. Roth D, Piekarek M, Paulsson M, et al. Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. Am J Pathol 2006;168:670-84.
12. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis, and vascular biology. J Thromb Haemost 2005;3:1800-14.
13. Tumber A, Papaioannou S, Breckon J, et al. The effects of serine proteinase inhibitors on bone resorption in vitro. J Endocrinol 2003;178:437-47.
14. Schoenecker J, Mignemi N, Stutz C, et al. 2010 Young Investigator Award winner: therapeutic aprotinin stimulates osteoblast proliferation but inhibits differentiation and bone matrix mineralization. Spine (Phila Pa 1976) 2010;35:1008-16.
15. Allan EH, Martin TJ. The plasminogen activator inhibitor system in bone cell function. Clin Orthop Relat Res 1995;313:54-63.
16. Daci E, Udagawa N, Martin TJ, et al. The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res 1999;14:946-52.
17. Firas KM, Kushagra V, Xavier S, et al. Epsilon aminocaproic and transexamic acid decrease osteoblast differentiation and mineralization in vitro. e-Poster presented at: Scoliosis Research Society 44th Annual Meeting & Course; September 23-26, 2009;San Antonio, TX.
18. Rao RD, Gourab K, Bagaria VB, et al. The effect of platelet-rich plasma and bone marrow on murine posterolateral lumbar spine arthrodesis with bone morphogenetic protein. J Bone Jt Surg 2009;91:1199-206.
19. Rao RD, Bagaria VB, Cooley BC. Posterolateral intertransverse lumbar fusion in a mouse model: surgical anatomy and operative technique. Spine J 2007;7:61-7.
20. Klak M, Anakkala N, Wang W, et al. Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis. Scand J Infect Dis 2010;42:351-8.
21. Schultz G, Tedesco MM, Sho E, et al. Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice. Arterioscler Thromb Vasc Biol 2010;30:1363-70.
22. Serkedjieva J, Nikolova E, Kirilov N. Synergistic inhibition of influenza A virus replication by a plant polyphenol-rich extract and epsilon-aminocaproic acid in vitro and in vivo. Acta Virol 2010;54:137-45.
23. Illanes S, Zhou W, Schwarting S, et al. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke 2011;42:191-5.
24. Lenke LG, Bridwell KH, Bullis D, et al. Results of in situ fusion for isthmic spondylolisthesis. J Spinal Dis 1992;5:433-42.
25. Mouton R, Finch D, Davies I, et al. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet 2008;371:475-82.
26. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31.
27. Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008;358:771-83.
28. Daci E, Everts V, Torrekens S, et al. Increased bone formation in mice lacking plasminogen activators. J Bone Miner Res 2003;18:1167-76.
29. Furlan F, Galbiati C, Jorgensen NR, et al. Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. J Bone Miner Res 2007;22:1387-96.
30. Fletcher DJ, Brainard BM, Epstein K, et al. Therapeutic plasma concentrations of epsilon-aminocaproic acid and tranexamic acid in horses. J Vet Intern Med 2013;27:1589-95.
31. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236-61.
32. Boxenbaum H, DiLea C. First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 1995;35:957-66.